[1]
|
Kawasaki, T. (2006) Kawasaki Disease. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 82, 59-71. https://doi.org/10.2183/pjab.82.59
|
[2]
|
Weiss, P.F. (2012) Pediatric Vasculitis. Pediatric Clinics of North America, 59, 407-423.
https://doi.org/10.1016/j.pcl.2012.03.013
|
[3]
|
McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Profes-sionals from the American Heart Association. Circulation, 135, 927-999. https://doi.org/10.1161/CIR.0000000000000484
|
[4]
|
梁翊常, 王乃坤, 柴晓敏. 我国川崎病概况[J]. 中国实用儿科杂志, 1995, 5(10): 302-303.
|
[5]
|
杜忠东, 陈笑征. 川崎病流行病学研究进展[J]. 中国实用儿科杂志, 2017, 32(8): 565-569.
|
[6]
|
张新艳, 杨婷婷, 何婷, 等. 2012至2016年单中心川崎病流行病学及临床特征研究[J]. 中国循证儿科杂志, 2018, 13(6): 427-432.
|
[7]
|
Hedrich, C., Schnabel, A. and Hospach, T. (2018) Kawasaki Disease. Frontiers in Pediatrics, 6, 198.
https://doi.org/10.3389/fped.2018.00198
|
[8]
|
阮瑜, 赵晓东. 川崎病诊断标准的变迁[J]. 儿科药学杂志, 2012, 18(1): 1-4.
|
[9]
|
余艳萍, 阿布来提•阿不都哈尔. 川崎病诊断与治疗新进展[J]. 中华临床医师杂志(电子版), 2016, 10(4): 566-570.
|
[10]
|
Kawasaki, T. (1967) Acute Febrile Mucocutaneous Syndrome with Lymphoid Involvement with Specific Desquamation of the Fingers and Toes in Children. Arerugi, 16, 178-222.
|
[11]
|
Kawasaki, T., Kosaki, F., Okawa, S., et al. (1974) A New Infantile Acute Febrile Mucocutaneous Lymph Node Syndrome (MLNS) Prevailing in Japan. Pediatrics, 54, 271-276.
|
[12]
|
Burns, J.C., Wiggins, J.W., Toews, W.H., et al. (1986) Clinical Spectrum of Ka-wasaki Disease in Infants Younger than 6 Months of Age. The Journal of Pediatrics, 109, 759-763. https://doi.org/10.1016/S0022-3476(86)80689-8
|
[13]
|
Kim, D.S. (2006) Kawasaki Disease. Yonsei Medical Journal, 47, 759-772. https://doi.org/10.3349/ymj.2006.47.6.759
|
[14]
|
O’Loughlin, J.E. (1989) Management of Kawasaki Syndrome: A Consensus Statement Prepared by North American Participants of the Third International Kawasaki Disease Symposium, Tokyo, Japan, December, 1988. The Pediatric Infectious Disease Journal, 8, 663-667. https://doi.org/10.1097/00006454-198910000-00001
|
[15]
|
Ayusawa, M., Sonobe, T., Uemura, S., et al. (2005) Revision of Diagnostic Guidelines for Kawasaki Disease (the 5th Revised Edition). Pediatrics International, 47, 232-234. https://doi.org/10.1111/j.1442-200x.2005.02033.x
|
[16]
|
Newburger, J.W., Taubert, K.A., Shulman, S.T., et al. (2003) Summary and Abstracts of the Seventh International Kawasaki Disease Symposium: December 4-7, 2001, Hakone, Japan. Pediatric Research, 53, 153-157.
https://doi.org/10.1203/00006450-200301000-00026
|
[17]
|
Burns, J.C., Kushner, H.I., Bastian, J.F., et al. (2000) Kawasaki Disease: A Brief History. Pediatrics, 106, 27.
https://doi.org/10.1542/peds.106.2.e27
|
[18]
|
Newburger, J.W., Takahashi, M., Gerber, M.A., et al. (2004) Diag-nosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals from the Committee on Rheumatic Fev, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 110, 2747-2771. https://doi.org/10.1161/01.CIR.0000145143.19711.78
|
[19]
|
Marchesi, A., Tarissi, I., Rigante, D., et al. (2018) Kawasaki Disease: Guidelines of the Italian Society of Pediatrics, Part I Definition, Epidemiology, Etiopathogenesis, Clinical Expression and Management of the Acute Phase. Italian Journal of Pediatrics, 44, 102. https://doi.org/10.1186/s13052-018-0536-3
|
[20]
|
Marchesi, A., Tarissi, I., Rigante, D., et al. (2018) Kawasaki Disease: Guidelines of Italian Society of Pediatrics, Part II Treatment of Resistant Forms and Cardiovascular Compli-cations, Follow-Up, Lifestyle and Prevention of Cardiovascular Risks. Italian Journal of Pediatrics, 44, 103. https://doi.org/10.1186/s13052-018-0529-2
|
[21]
|
Pilania, R.K., Bhattarai, D. and Singh, S. (2018) Controversies in Diagnosis and Management of Kawasaki Disease. World Journal of Clinical Pediatrics, 7, 27-35. https://doi.org/10.5409/wjcp.v7.i1.27
|
[22]
|
Moore, A., Harnden, A. and Mayon-White, R. (2014) Recognising Kawasaki Disease in UK Primary Care: A Descriptive Study Using the Clinical Practice Research Datalink. British Journal of General Practice, 64, e477-e483.
https://doi.org/10.3399/bjgp14X680953
|
[23]
|
Boudiaf, H. and Achir, M. (2016) The Clinical Profile of Kawasaki Disease in Algerian Children: A Single Institution Experience. Journal of Tropical Pediatrics, 62, 139-143. https://doi.org/10.1093/tropej/fmv090
|
[24]
|
Rowley, A.H. (2015) The Complexities of the Diagnosis and Man-agement of Kawasaki Disease. Infectious Disease Clinics of North America, 29, 525-537. https://doi.org/10.1016/j.idc.2015.05.006
|
[25]
|
Seo, Y.-M., Kang, H.-M., Lee, S.-C., et al. (2018) Clinical Impli-cations in Laboratory Parameter Values in Acute Kawasaki Disease for Early Diagnosis and Proper Treatment. Korean Journal of Pediatrics, 61, 160-166.
https://doi.org/10.3345/kjp.2018.61.5.160
|
[26]
|
赵晓东, 杜忠东. 川崎病专题讨论会纪要[J]. 中华儿科杂志, 2007, 45(11): 826-830.
|
[27]
|
李雪琴, 吕菊红, 李文君. 血浆端脑利钠肽前体测定在不完全川崎病患儿早期诊断的临床意义[J]. 山西医科大学学报, 2014, 45(3): 227-229.
|
[28]
|
王祥, 陈智, 肖云彬, 等. 血N末端脑利钠肽原和降钙素原在川崎病诊断中的价值[J]. 中国中西医结合儿科学, 2017, 9(4): 301-303.
|
[29]
|
李雪琴, 吕菊红, 李文君. 血浆N末端B型利钠肽原与C反应蛋白在小儿川崎病中的变化及临床意义[J]. 中国临床研究, 2014, 27(5): 583-584.
|
[30]
|
张丽君. 血清淀粉样蛋白A检测在儿童川崎病诊断中的价值[J]. 预防医学论坛, 2018, 24(5): 390-392.
|
[31]
|
陈灵红, 林红霞, 杨德华. 血清淀粉样蛋白A对川崎病诊断的临床应用价值[J]. 浙江中西医结合杂志, 2017, 27(9): 770-773.
|
[32]
|
邓永超, 唐喜春, 杨娟, 等. 平均血小板质量与降钙素原在儿童川崎病诊断中的应用价值[J]. 现代检验医学杂志, 2016, 31(5): 144-146.
|
[33]
|
郑瑞利, 何坤, 董湘玉. 川崎病易感基因的研究进展[J]. 中西医结合心血管病杂志, 2017, 5(33): 18-21.
|
[34]
|
吴镇宇, 姚丽萍. 与川崎病发病及冠状动脉损伤相关的易感基因[J]. 中外医疗, 2016, 35(16): 197-198.
|
[35]
|
蒋勇, 李敬风. FCGR2A基因rs1801274位点基因多态性与川崎病相关性研究的Meta分析[J]. 现代医学, 2017, 45(4): 465-471.
|